What are the essential pre‑procedural assessments, intra‑procedural management steps, and post‑procedural care recommendations a physician assistant should follow when assisting with interventional cardiology (percutaneous coronary intervention) cases?

Essential Knowledge for Physician Assistants in Interventional Cardiology

As a PA assisting with interventional cardiology procedures, you must master pre-procedural risk assessment, periprocedural antiplatelet/anticoagulation management, vascular access strategies, and post-procedural complication recognition—with bleeding avoidance and dual antiplatelet therapy (DAPT) adherence being your highest priorities for reducing mortality and morbidity. 1, 2

Pre-Procedural Assessment

Risk Stratification (Mandatory Before Every Case)

• Assess bleeding risk in every patient before PCI—this directly impacts mortality and must guide your anticoagulation choices 1
• Evaluate for contrast-induced acute kidney injury (AKI) risk by checking baseline creatinine clearance; patients with CKD (creatinine clearance <60 mL/min) require minimized contrast volume 1
• Calculate estimated glomerular filtration rate (eGFR) and adjust all renally cleared medication doses accordingly—this includes anticoagulants and is a Class I recommendation 1
• Identify high-risk features: age ≥70 years, body surface area <1.6 m², emergency procedures, peripheral artery disease, female sex (if not corrected for body surface area), baseline anemia, low body mass index 1

Contrast Nephropathy Prevention

• Administer adequate preparatory hydration before cardiac catheterization—this is a Class I, Level B recommendation 1
• Do NOT give N-acetyl-L-cysteine for contrast-induced AKI prevention—it has no benefit (Class III: No Benefit, Level A) 1
• Minimize contrast volume in patients with CKD (Class I, Level B) 1

Allergy Management

• Pretreat patients with prior anaphylactoid reactions to contrast media with steroids and H1-blocker (Class I, Level B) 1, 3
• Do NOT provide anaphylactoid prophylaxis for shellfish/seafood allergies—this is not beneficial (Class III: No Benefit, Level C) 1

Antiplatelet Loading (Critical for Stent Thrombosis Prevention)

For patients already on aspirin:

• Continue 81-325 mg daily before PCI (Class I, Level B) 1, 2

For aspirin-naïve patients:

• Give non-enteric aspirin 325 mg before PCI (Class I, Level B) 1
• Administer aspirin 162-325 mg preferably prior to catheterization 2

P2Y12 inhibitor loading:

• Administer clopidogrel 600 mg loading dose in the periprocedural period 2
• This is the recommended agent for patients on anticoagulation 2

Statin Therapy

• Administer high-dose statin before PCI to reduce periprocedural MI risk (Class IIa, Level A for statin-naïve patients; Level B for chronic statin therapy) 1

Intra-Procedural Management

Vascular Access Strategy (Bleeding Reduction Priority)

• Strongly recommend radial artery access over femoral access—this significantly decreases access-related bleeding and complications (Class I recommendation) 2
• Radial access reduces mortality compared to femoral approach 2
• Be prepared for 5-10% crossover rate to femoral access 2
• Use vascular closure devices for femoral access when radial is not feasible to minimize bleeding 2

Intraprocedural Anticoagulation (All Class I)

Choose one of three options (all have Class I recommendations per ACC/AHA guidelines): 2

• Unfractionated heparin
• Low-molecular-weight heparin (LMWH)
• Bivalirudin

Follow guideline-specified dosing protocols exactly 2

Adjunctive Therapies (Use Selectively)

• Consider glycoprotein IIb/IIIa inhibitor or cangrelor for fresh thrombus or patients without P2Y12 inhibitor pretreatment 2
• Recognize these agents increase bleeding risk significantly 2

Stent Selection

• Use newest-generation drug-eluting stents (DES) even in high bleeding risk patients—do NOT use bare metal stents 2

Post-Procedural Care

Immediate Post-Procedure Monitoring

Vascular access site complications (2-6% incidence): 1

• Assess for access site hemostasis immediately—this is your first priority before restarting anticoagulation 2
• Monitor for groin/flank/abdominal/back pain, hypotension, or hematocrit drop—these indicate retroperitoneal hematoma 1, 3
• Examine for groin tenderness, pulsatile mass, or bruit—these suggest pseudoaneurysm or arteriovenous fistula 1, 3
• Check for radial pulse loss (occurs in 5% of radial procedures) 1

Ischemic complications:

• Monitor clinically for evidence of ongoing ischemia 3
• Recognize that typical anginal symptoms between 1-8 months post-PCI likely represent restenosis and require imaging or repeat catheterization 3

Stroke risk:

• Stroke occurs in approximately 0.2-0.4% of cases 1
• Refer to AHA/American Stroke Association guidelines for management 1

Dual Antiplatelet Therapy (DAPT) Management

This is the most critical post-procedural responsibility—stent thrombosis is catastrophic.

Aspirin dosing: 4

• Give aspirin 325 mg daily for at least 1 month after bare metal stent (BMS) (Class I, Level B)
• Give aspirin 325 mg daily for 3 months after sirolimus-eluting stent (Class I, Level B)
• Give aspirin 325 mg daily for 6 months after paclitaxel-eluting stent (Class I, Level B)
• After initial period, continue low-dose aspirin 75-162 mg daily indefinitely (Class I, Level B) 4
• In bleeding-concerned patients, use lower-dose aspirin 75-162 mg even during initial period (Class IIa, Level C) 4

Clopidogrel dosing: 4

• Give clopidogrel 75 mg daily for at least 1 month after BMS (Class I, Level B)
• Give clopidogrel 75 mg daily for 3 months after sirolimus-eluting stent (Class I, Level B)
• Give clopidogrel 75 mg daily for 6 months after paclitaxel-eluting stent (Class I, Level B)
• Ideally continue clopidogrel up to 12 months in all stented patients not at high bleeding risk (Class I, Level B) 4

For STEMI patients without stent:

• Continue clopidogrel for at least 14 days (Class I, Level B) 4

Long-term maintenance:

• Long-term clopidogrel (1 year) is reasonable in STEMI/NSTEMI patients who undergo PCI (Class IIa, Level C) 4

Anticoagulation Reinitiation (For Patients on Chronic Anticoagulation)

Timing: 2

• Resume anticoagulation within 24 hours post-PCI in most patients—may be same evening depending on hemostasis
• Collaborate with interventional cardiologist before restarting

Agent selection: 2

• Prefer direct oral anticoagulant (DOAC) over warfarin post-PCI (Class I recommendation)
• If warfarin is used, target INR 2.0-2.5 (not 2.5-3.5) when combined with aspirin and clopidogrel 4
• Use low-dose aspirin 75-81 mg with clopidogrel 75 mg when on triple therapy 4

Bridging considerations: 2

• Do NOT bridge DOACs with LMWH—no value and increases bleeding
• Only bridge warfarin in small subset with very high thromboembolic risk
• Consider continuing aspirin + P2Y12 inhibitor until INR therapeutic if not bridging

Dose adjustments: 2

• Adjust DOAC and LMWH doses based on post-PCI renal function
• For rivaroxaban in atrial fibrillation: use 15 mg daily if CrCl >50 mL/min, 10 mg daily if CrCl 30-50 mL/min (based on PIONEER-AF PCI trial) 2

ACE Inhibitors/ARBs (Secondary Prevention)

ACE inhibitors: 4

• Start and continue indefinitely in all patients with LVEF ≤40% (Class I, Level A)
• Start and continue indefinitely in patients with hypertension, diabetes, or chronic kidney disease (Class I, Level A)
• Start in non-lower-risk patients (Class I, Level B)
• Reasonable in lower-risk patients with normal LVEF and controlled risk factors (Class IIa, Level B)

Angiotensin receptor blockers (ARBs): 4

• Use in ACE inhibitor-intolerant patients with heart failure or MI with LVEF ≤40% (Class I, Level A)
• Use in ACE inhibitor-intolerant patients with hypertension (Class I, Level B)

Aldosterone blockade: 4

• Use in post-MI patients already on ACE inhibitor and beta blocker, with LVEF ≤40% and diabetes or heart failure—exclude significant renal dysfunction or hyperkalemia (Class I, Level A)

Risk Factor Management

Coordinate with primary care/endocrinology for: 4

• Diabetes management (Class I, Level C)
• Physical activity, weight management, blood pressure, cholesterol management (Class I, Level B)

Same-Day Discharge Checklist (When Appropriate)

Ensure completion of: 5

• DAPT loading dose administered and confirmed
• Prescription for P2Y12 inhibitor sent to facility and patient's outpatient pharmacy
• Aspirin and statin prescriptions confirmed
• Cardiac rehabilitation referral placed
• Discharge instructions documented
• Reliable caregiver identified for transport and monitoring
• Access site and overall condition stable

Common Pitfalls to Avoid

• Never use enteric-coated aspirin for loading—it delays absorption 6
• Never discontinue aspirin perioperatively 6
• Never assume adequate platelet inhibition if aspirin given <2 hours before procedure 6
• Never use bare metal stents to "reduce DAPT duration" in bleeding-risk patients—use newest-generation DES 2
• Never restart anticoagulation without assessing access site hemostasis 2
• Never bridge DOACs with LMWH—pharmacokinetics are similar and bleeding risk increases 2
• Never forget to adjust renally cleared medications post-procedure 1
• Never give N-acetyl-cysteine for contrast nephropathy prevention—it doesn't work 1